Halozyme Therapeutics Inc (HALO)

[Percysixstargazer]

Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme

06/25/2014

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems


SAN DIEGO, June 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera® SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin® SC in September 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche's oncology products using Halozyme's patented EnhanzeTM (recombinant human hyaluronidase) technology to be launched in Europe.

The approval of MabThera SC in Europe in March 2014 for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma was primarily based on a clinical development program which showed that SC administration enabled the delivery of MabThera over approximately five minutes versus 2.5 hours intravenously without compromising its proven efficacy and safety. This innovative formulation could potentially save time for patients, physicians and other health care providers in Europe.